Atypical antipsychotic drugs are a type of antipsychotic drugs used in treatment of psychosis. They do not cure psychosis but help in controlling symptoms such as hallucinations, and delusions, among others.
LPI (LP Information)' newest research report, the “Atypical Antipsychotic Drugs Industry Forecast” looks at past sales and reviews total world Atypical Antipsychotic Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Atypical Antipsychotic Drugs sales for 2023 through 2029. With Atypical Antipsychotic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Atypical Antipsychotic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Atypical Antipsychotic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Atypical Antipsychotic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Atypical Antipsychotic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Atypical Antipsychotic Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Atypical Antipsychotic Drugs.
The global Atypical Antipsychotic Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Atypical Antipsychotic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Atypical Antipsychotic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Atypical Antipsychotic Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Atypical Antipsychotic Drugs players cover Novartis AG, Cardinal Health, Johnson and Johnson, Allergan, Sanis Health, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb Company and Sun Pharmaceutical Industries, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Atypical Antipsychotic Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Risperidone
Olanzapine
Quetiapine
Ziprasidone
Others
Segmentation by application
Bipolar I Disorder
Schizophrenia
Schizoaffective Disorder
Major Depressive Disorder (MDD)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis AG
Cardinal Health
Johnson and Johnson
Allergan
Sanis Health
Pfizer
GlaxoSmithKline
Bristol-Myers Squibb Company
Sun Pharmaceutical Industries
Eil Lilly and Company
AstraZeneca
Sumitomo Dainippon Pharma
Qilu Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Atypical Antipsychotic Drugs market?
What factors are driving Atypical Antipsychotic Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Atypical Antipsychotic Drugs market opportunities vary by end market size?
How does Atypical Antipsychotic Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Atypical Antipsychotic Drugs Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for Atypical Antipsychotic Drugs by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for Atypical Antipsychotic Drugs by Country/Region, 2018, 2022 & 2029 2.2 Atypical Antipsychotic Drugs Segment by Type 2.2.1 Risperidone 2.2.2 Olanzapine 2.2.3 Quetiapine 2.2.4 Ziprasidone 2.2.5 Others 2.3 Atypical Antipsychotic Drugs Sales by Type 2.3.1 Global Atypical Antipsychotic Drugs Sales Market Share by Type (2018-2023) 2.3.2 Global Atypical Antipsychotic Drugs Revenue and Market Share by Type (2018-2023) 2.3.3 Global Atypical Antipsychotic Drugs Sale Price by Type (2018-2023) 2.4 Atypical Antipsychotic Drugs Segment by Application 2.4.1 Bipolar I Disorder 2.4.2 Schizophrenia 2.4.3 Schizoaffective Disorder 2.4.4 Major Depressive Disorder (MDD) 2.5 Atypical Antipsychotic Drugs Sales by Application 2.5.1 Global Atypical Antipsychotic Drugs Sale Market Share by Application (2018-2023) 2.5.2 Global Atypical Antipsychotic Drugs Revenue and Market Share by Application (2018-2023) 2.5.3 Global Atypical Antipsychotic Drugs Sale Price by Application (2018-2023) 3 Global Atypical Antipsychotic Drugs by Company 3.1 Global Atypical Antipsychotic Drugs Breakdown Data by Company 3.1.1 Global Atypical Antipsychotic Drugs Annual Sales by Company (2018-2023) 3.1.2 Global Atypical Antipsychotic Drugs Sales Market Share by Company (2018-2023) 3.2 Global Atypical Antipsychotic Drugs Annual Revenue by Company (2018-2023) 3.2.1 Global Atypical Antipsychotic Drugs Revenue by Company (2018-2023) 3.2.2 Global Atypical Antipsychotic Drugs Revenue Market Share by Company (2018-2023) 3.3 Global Atypical Antipsychotic Drugs Sale Price by Company 3.4 Key Manufacturers Atypical Antipsychotic Drugs Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Atypical Antipsychotic Drugs Product Location Distribution 3.4.2 Players Atypical Antipsychotic Drugs Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Atypical Antipsychotic Drugs by Geographic Region 4.1 World Historic Atypical Antipsychotic Drugs Market Size by Geographic Region (2018-2023) 4.1.1 Global Atypical Antipsychotic Drugs Annual Sales by Geographic Region (2018-2023) 4.1.2 Global Atypical Antipsychotic Drugs Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic Atypical Antipsychotic Drugs Market Size by Country/Region (2018-2023) 4.2.1 Global Atypical Antipsychotic Drugs Annual Sales by Country/Region (2018-2023) 4.2.2 Global Atypical Antipsychotic Drugs Annual Revenue by Country/Region (2018-2023) 4.3 Americas Atypical Antipsychotic Drugs Sales Growth 4.4 APAC Atypical Antipsychotic Drugs Sales Growth 4.5 Europe Atypical Antipsychotic Drugs Sales Growth 4.6 Middle East & Africa Atypical Antipsychotic Drugs Sales Growth 5 Americas 5.1 Americas Atypical Antipsychotic Drugs Sales by Country 5.1.1 Americas Atypical Antipsychotic Drugs Sales by Country (2018-2023) 5.1.2 Americas Atypical Antipsychotic Drugs Revenue by Country (2018-2023) 5.2 Americas Atypical Antipsychotic Drugs Sales by Type 5.3 Americas Atypical Antipsychotic Drugs Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Atypical Antipsychotic Drugs Sales by Region 6.1.1 APAC Atypical Antipsychotic Drugs Sales by Region (2018-2023) 6.1.2 APAC Atypical Antipsychotic Drugs Revenue by Region (2018-2023) 6.2 APAC Atypical Antipsychotic Drugs Sales by Type 6.3 APAC Atypical Antipsychotic Drugs Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Atypical Antipsychotic Drugs by Country 7.1.1 Europe Atypical Antipsychotic Drugs Sales by Country (2018-2023) 7.1.2 Europe Atypical Antipsychotic Drugs Revenue by Country (2018-2023) 7.2 Europe Atypical Antipsychotic Drugs Sales by Type 7.3 Europe Atypical Antipsychotic Drugs Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Atypical Antipsychotic Drugs by Country 8.1.1 Middle East & Africa Atypical Antipsychotic Drugs Sales by Country (2018-2023) 8.1.2 Middle East & Africa Atypical Antipsychotic Drugs Revenue by Country (2018-2023) 8.2 Middle East & Africa Atypical Antipsychotic Drugs Sales by Type 8.3 Middle East & Africa Atypical Antipsychotic Drugs Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Atypical Antipsychotic Drugs 10.3 Manufacturing Process Analysis of Atypical Antipsychotic Drugs 10.4 Industry Chain Structure of Atypical Antipsychotic Drugs 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Atypical Antipsychotic Drugs Distributors 11.3 Atypical Antipsychotic Drugs Customer 12 World Forecast Review for Atypical Antipsychotic Drugs by Geographic Region 12.1 Global Atypical Antipsychotic Drugs Market Size Forecast by Region 12.1.1 Global Atypical Antipsychotic Drugs Forecast by Region (2024-2029) 12.1.2 Global Atypical Antipsychotic Drugs Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Atypical Antipsychotic Drugs Forecast by Type 12.7 Global Atypical Antipsychotic Drugs Forecast by Application 13 Key Players Analysis 13.1 Novartis AG 13.1.1 Novartis AG Company Information 13.1.2 Novartis AG Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.1.3 Novartis AG Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 Novartis AG Main Business Overview 13.1.5 Novartis AG Latest Developments 13.2 Cardinal Health 13.2.1 Cardinal Health Company Information 13.2.2 Cardinal Health Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.2.3 Cardinal Health Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 Cardinal Health Main Business Overview 13.2.5 Cardinal Health Latest Developments 13.3 Johnson and Johnson 13.3.1 Johnson and Johnson Company Information 13.3.2 Johnson and Johnson Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.3.3 Johnson and Johnson Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 Johnson and Johnson Main Business Overview 13.3.5 Johnson and Johnson Latest Developments 13.4 Allergan 13.4.1 Allergan Company Information 13.4.2 Allergan Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.4.3 Allergan Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 Allergan Main Business Overview 13.4.5 Allergan Latest Developments 13.5 Sanis Health 13.5.1 Sanis Health Company Information 13.5.2 Sanis Health Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.5.3 Sanis Health Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 Sanis Health Main Business Overview 13.5.5 Sanis Health Latest Developments 13.6 Pfizer 13.6.1 Pfizer Company Information 13.6.2 Pfizer Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.6.3 Pfizer Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 Pfizer Main Business Overview 13.6.5 Pfizer Latest Developments 13.7 GlaxoSmithKline 13.7.1 GlaxoSmithKline Company Information 13.7.2 GlaxoSmithKline Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.7.3 GlaxoSmithKline Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 GlaxoSmithKline Main Business Overview 13.7.5 GlaxoSmithKline Latest Developments 13.8 Bristol-Myers Squibb Company 13.8.1 Bristol-Myers Squibb Company Company Information 13.8.2 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.8.3 Bristol-Myers Squibb Company Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 Bristol-Myers Squibb Company Main Business Overview 13.8.5 Bristol-Myers Squibb Company Latest Developments 13.9 Sun Pharmaceutical Industries 13.9.1 Sun Pharmaceutical Industries Company Information 13.9.2 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.9.3 Sun Pharmaceutical Industries Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.9.4 Sun Pharmaceutical Industries Main Business Overview 13.9.5 Sun Pharmaceutical Industries Latest Developments 13.10 Eil Lilly and Company 13.10.1 Eil Lilly and Company Company Information 13.10.2 Eil Lilly and Company Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.10.3 Eil Lilly and Company Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.10.4 Eil Lilly and Company Main Business Overview 13.10.5 Eil Lilly and Company Latest Developments 13.11 AstraZeneca 13.11.1 AstraZeneca Company Information 13.11.2 AstraZeneca Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.11.3 AstraZeneca Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.11.4 AstraZeneca Main Business Overview 13.11.5 AstraZeneca Latest Developments 13.12 Sumitomo Dainippon Pharma 13.12.1 Sumitomo Dainippon Pharma Company Information 13.12.2 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.12.3 Sumitomo Dainippon Pharma Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.12.4 Sumitomo Dainippon Pharma Main Business Overview 13.12.5 Sumitomo Dainippon Pharma Latest Developments 13.13 Qilu Pharmaceutical 13.13.1 Qilu Pharmaceutical Company Information 13.13.2 Qilu Pharmaceutical Atypical Antipsychotic Drugs Product Portfolios and Specifications 13.13.3 Qilu Pharmaceutical Atypical Antipsychotic Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.13.4 Qilu Pharmaceutical Main Business Overview 13.13.5 Qilu Pharmaceutical Latest Developments 14 Research Findings and Conclusion